Botulinium Toxin-A

2

Review clinical trials related to Botulinium Toxin-A. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Comparative Evaluation of Intraneuroma and Perineuroma Botulinum Toxin Type A Injection Techniques for Chronic Neuroma Pain After Combat-Related Amputation

Patients with combat-related amputations frequently experience chronic neuroma pain that may interfere with rehabilitation, prosthesis use, mobility, sleep, and quality of life. Ultrasound-guided botulinum toxin type A injection has emerged as a potential treatment option for persistent neuroma pain; however, the optimal injection technique remains unclear. This prospective multicenter study aims to compare two ultrasound-guided botulinum toxin injection techniques for chronic neuroma pain after combat-related amputation: intraneuroma injection and perineuroma injection. Participants with ultrasound-confirmed painful neuromas will undergo one of the two injection approaches based on the treating physician's clinical decision and local practice. Pain intensity, neuropathic pain characteristics, phantom limb pain, prosthesis tolerance, functional outcomes, and adverse events will be evaluated during follow-up. The goal of the study is to evaluate the feasibility, safety, and potential clinical effectiveness of intraneuroma and perineuroma botulinum toxin type A injection techniques in patients with chronic neuroma pain following combat-related amputation.

Participants needed: 100
Trial details
Age: 18-60Biological sex: AllType: InterventionalSponsor: Ukrainian Society of Regional Anesthesia and Pain TherapyUpdated: Jun 3, 2026Locations: 2
Eligibility criteria

Age ≥18 years [+7]

Active infection at or near the injection site [+7]

Status: Recruiting

Local Injection of Botulinium Toxin-A in Children With Dysfunctional Voiding or Refractory Nocturnal Eneuresis

The aim of this study is to evaluate the outcome of botulinum toxin A (BTX-A) injection for management of children with : A-Dysfunctional voiding who are not responding to traditional treatment. B-Refractory nocturnal enuresis.

Participants needed: 64
Trial details
Age: Up to 18Biological sex: AllType: InterventionalSponsor: Tanta UniversityUpdated: Apr 13, 2026Locations: 1
Eligibility criteria

Children < 18 years. [+2]

Bleeding disorders. [+3]